key: cord-1009723-z6my1d83
authors: Slimano, Florian; Baudouin, Amandine; Zerbit, Jérémie; Toulemonde-Deldicque, Anne; Thomas-Schoemann, Audrey; Chevrier, Régine; Daouphars, Mikaël; Madelaine, Isabelle; Pourroy, Bertrand; Tournamille, Jean-François; Astier, Alain; Ranchon, Florence; Cazin, Jean-Louis; Bardin, Christophe; Rioufol, Catherine
title: Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety
date: 2020-06-23
journal: Cancer Treat Rev
DOI: 10.1016/j.ctrv.2020.102063
sha: e1ad1374aa168ec27f0e5979a17e8b675afebe21
doc_id: 1009723
cord_uid: z6my1d83

Abstract The Coronavirus disease (COVID-19) pandemic is disrupting our health environment. As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to deeply rethink patient cancer care. This review is dedicated to the optimization of care pathways and therapeutics in cancer patients during the pandemic and aims to discuss successive issues. First we focused on the international guidelines proposing adjustments and alternative options to cancer care in order to limit hospital admission and cytopenic treatment in cancer patients, most of whom are immunocompromised. In addition cancer patients are prone to polypharmacy, enhancing the risk of drug-related problems as adverse events and drug-drug interactions. Due to increased risk in case of COVID-19, we reported a comprehensive review of all the drug-related problems between COVID-19 and antineoplastics. Moreover, in the absence of approved drug against COVID-19, infected patients may be included in clinical trials evaluating new drugs with a lack of knowledge, particularly in cancer patients. Focusing on the several experimental drugs currently being evaluated, we set up an original data board helping oncologists and pharmacists to identify promptly drug-related problems between antineoplastics and experimental drugs. Finally additional and concrete recommendations are provided, supporting oncologists and pharmacists in their efforts to manage cancer patients and to optimize their treatments in this new era related to COVID-19.

The increased susceptibility of cancer patients to viral respiratory infection is well known, implicating both disease and treatment [4, 5] . Risk is higher in lymphopenia affecting cell immune function and antibody-mediated immunity [6] . Impaired lymphocyte function [7] and neutropenia [5] are further risk factors, as are monoclonal antibody treatment against lymphocyte antigens and above all hematopoietic stem-cell (HSC) allograft [7] . Cancer patients, especially lung cancer patients with associated respiratory disorder or ischemic cardiopathy, are also at high risk of severe infection [8] . For influenza, rates of hospital admission and mortality are respectively 4-and 10-fold higher in cancer patients than in the general population [9] . Coronavirus patients (excluding SARS-CoV-2) show significantly greater 30-day mortality in case of cancer (24.4% vs 3.0%, p<0.001) [10] . Cancer was shown to be the main factor in 30-day mortality on multivariate analysis (p<0.001), ahead of age >65 years (p=0.026), bacterial superinfection (p=0.031), and initial state of shock (p=0.042) [10] .

The first data from a multicenter Chinese cohort of 1,590 COVID-19 positive patients showed comorbidities to be a risk factor for contamination, severe manifestations and early death [11] . Patients with history of or active cancer showed higher risk of infection (1.13% versus 0.29% in the general population). Most of all, cancer patients (n=18) deteriorated more rapidly (hazard ratio (HR)=3.56 (95%CI, 1.65-7.69)) [8] . Allowing for the limitations of the study and notably the small sample, the authors considered cancer patients' immune depression to be the prime cause of poor prognosis. A second Chinese series of 1,276 patients in the Wuhan region found 2.2% prevalence of SARS-CoV-2 in cancer patients (28 infected) , and 28.6% mortality: i.e., 1.7-fold greater prevalence (95%CI, 1.2-2.4) and 10-fold greater mortality than in the general population. Patients with anticancer treatment during the previous 14 days showed greater risk of mortality (HR= 4.08, 95%CI, 11-15. 3, p=0.037) [12] . Among 1,524 patients followed for cancer in a Wuhan hospital, there was SARS-CoV-2 contamination in 12 cases (0.79%; 95%CI, 0.3-1.2%), higher than Wuhan population (0.37%). More than half the COVID-19+ patients (58.3%) had lung cancer and age >60 years was a factor for extra risk (4.3% versus 1.8%) [13] . Other factors reported to aggravate COVID-19 infection in cancer patients include comorbidity such as type-2 diabetes, chronic kidney failure [14] or cardiovascular disease [15] . Most of the epidemiological studies are based on Chinese cohorts and caution is needed for the extrapolation to other countries with different comorbidity

prevalence. An Italian study reports a prevalence of 20.3% (n=72) patients with active cancer among 355 patients who died from COVID-19 [16] . Moreover, such patients are often polymedicated [17, 18] , receiving drugs with narrow therapeutic index (antineoplastics, immunosuppressants) exposing COVID-19+ patients with symptoms to increased risk of drug interactions and potentialization of adverse effects.

Moreover, other risks, related to quarantine, need to be taken into account in managing cancer and its complications: Wang et al. notably report problems of access to health-care, drug shortages and delay in diagnosis of treatment toxicity [19] . The poor prognosis of cancer patients admitted with COVID-19 infection was also due to the decision not to admit certain (metastatic) patients to intensive care.

On the basis of these preliminary data, at least 3 consequences of the pandemic for the management of cancer patients can be raised:

-Cancer patients seem more susceptible to SARS-CoV-2 infection, and complications (hospital admission, intensive care, death) are probably more frequent than in the general population [8, 12] .

-COVID-19+ cancer patients show greater risk of iatrogenic drug-related problems, due to polymedication [20] .

-The pandemic is tying up considerable human and economic resources and care activity is frequently rescheduled or cancelled, temporarily modifying cancer patient management. The lack of large clinical studies in cancer patients facing COVID-19 lead scientific societies and expert groups guidelines to advocate postponing surgery and drug treatment in some cases. The delay of cancer diagnoses has to be assessed in the months to come [21] .

The aim of the present guidelines is to review and report a summary of the various recommendations / expert consensus published by scientific societies or oncology groups for the management of cancer patients in the context of the COVID-19 pandemic. We will focus on drug-related problems facing a polymedicated and fragile population (drug interactions, potentialization of symptoms and adverse effects), including molecules undergoing clinical trials. Finally, the ability of clinical oncology pharmacy to limit the risk of contamination and to manage drug-related problems in cancer patients will be assessed.

There are two emerging risks for cancer patients: a 3-fold greater infection risk than in the general population (associated with poor prognosis and greater mortality) and the risk of delayed access to diagnosis, current care and therapeutic innovations. The challenge is thus to assess, on a case-by-case basis, the trade-off between delayed diagnosis and treatment of cancer and exposure to SARS-CoV-2.

To limit the risk of SARS-CoV-2 contamination and the risks associated with cancer treatments, 

The management of cancer patient's treatment continues to be discussed case by case into the management case conferences and clinicians are required to take decisions for protecting patients regarding the emerging risk. The lack of published data or conducted clinical studies makes it difficult to take the right therapeutic decision. Because of the emergency situation, the summary of recommendations cannot be based solely on the highest evidence, clinical trials and meta-analyses. Adaptations as modified, delayed or discontinued anticancer treatments were suggested mainly based on expert consensus. In addition the first Chinese series are lacking of consistency for demonstrating the significant risk in cancer patients [29] . Regarding the association with severity of COVID-19, however, a recent analysis from the Montefiore Medical Center in New York among 218 cancer patients suggested an association between cancer patients and COVID-19 related fatality in particular for hematologic malignancies (case fatality rate of 37% versus 25% for solid malignancies) [30] . The authors conclude that there is a need for proactive strategies to reduce likelihood of infection and improve early identification in this vulnerable patient population.

It appears reasonable to limit hospital visit for cancer patients including for receiving anticancer treatment but, in the other hand, it seems challenging to suggest discontinuing an active anticancer treatment after several months of treatment. Hanna [32, 33] . On the other hand, the replacement of fluorouracil by capecitabin for adjuvant colorectal cancer patients is based on evidence [34] .

The following factors need to be taken into account: curative or palliative objective; patient age (with increased risk from 60 or and 70 years, depending on the report, in lung [13] or digestive/colorectal cancer [35] [43] . Caution is nevertheless required due to possible cumulative risk with COVID-19 symptoms, with rare but severe interstitial pneumopathy aggravating the pulmonary damage [44] . Such cumulative risk may also occur with certain oral antineoplastics such as everolimus, crizotinib, and trametinib [45] . Some authors also suggested cumulative risk of cytokine release syndrome between immune checkpoint inhibitors or CAR-T cells and cytokine storm in severe COVID-19 infection [44] .

Expert opinion favors postponing immunotherapy if possible, especially in case of associations such as nivolumab-ipilimumab and in stable diseases [35, 46] [80] . The Table   1 reports this suggestion of at least 2 years of treatment to consider discontinuation.

The fact that COVID-19 emerged so recently means that data are controversial. It has been suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may exacerbate the risk of respiratory and cardiac complications in various situations of infection, and thus likely in severe forms of COVID-19 [81] . Regarding corticosteroids, a meta-analysis performed by the WHO following the SARS-CoV epidemic found no harmful effects [82] ; in COVID-19, clinical trials using corticosteroids are ongoing especially in the early stage of respiratory distress syndrome.

In the absence of firm evidence, corticotherapy should be avoided whenever possible, and any prescription of high-dose corticosteroids, including for anticancer purposes, needs to be assessed on a case-by-case basis as seen in Table 1 for dexamethasone in multiple myeloma patients [73] . The use of corticosteroid as antiemetic does not reach a consensus [35, 83] .

In cancer patients, diagnosis of COVID-19+ indicates admission to a specialized COVID-19 unit, or transfer for oncology inpatients. In oncology centers, dedicated COVID-19 units, 

The protease inhibitor association lopinavir and ritonavir is commonly used to treat HIV-1 infection. Some in-vitro and clinical data demonstrated its activity on SARS-CoV-2 virus. The dosage used for COVID-19 is the same as HIV-1 treatment: 400/100mg, twice daily for 7 to 14 days.

Lopinavir and ritonavir are strong inhibitors of cytochrome P450 isoform CYP3A, thus increasing the concentration of numerous CYP-substrate drugs. They are also efflux protein Pgp inhibitors leading to increased concentration of P-gp substrates. Interactions are numerous, notably with narrow-window treatments. Among oral antineoplastics, Liver cytochrome metabolized Kinase Inhibitors (including TKIs and others) should be avoided in association to lopinavir/ritonavir. If TKIs continuation is needed, dose reduction and monitoring of TKIrelated adverse events are advised (Table 2A) . It is important to note that drug-interaction impact may be different according to the database. Some support treatments such as hydroxyzine, oxycodone and zopiclone, often prescribed for cancer patients should be avoided or at least closely monitored when associated to 3A4 inhibitor or antiretroviral drugs with cardiac toxicity. In hematologic cancer patients with HSC graft, the benefit of lopinavir and ritonavir needs weighing against the increased risk of post-graft immunosuppressive treatment imbalance and resultant complications such as graft-versus-host disease (GVHD). Lopinavir and ritonavir are also CYP3A4 substrates, and concomitant moderate or powerful inducers require special vigilance. Dabrafenib and enzalutamide can continue to impair the efficacy of antiretrovirals for several days after discontinuation, with risk of failure of COVID-19 treatment.

Cardiotoxicity by QT prolongation is frequent with lopinavir and ritonavir ( Table 3) . Many

TKIs, doxorubicin and ondansetron seriously increase QT interval and should not be associated to lopinavir or ritonavir ( Table 3) . The same is true for serotonin reuptake inhibitors, frequently prescribed for depression in cancer patients [84] . Autoimmune diseases, and notably hepatitis and pancreatitis, have been reported with lopinavir and ritonavir, which should not be used if immune checkpoint inhibitors are continued.

Hydroxychloroquine is used to prevent systemic lupus episodes and other autoimmune and inflammatory diseases. Its activity involves viral infection inhibition (experimental) and

immunomodulation contributing to control of the cytokine storm that occurs in the late stage of COVID-19 infection. A loading dose at Day 1 followed up by 400mg daily dose for 9 days is usually reported in studies. The loading dose is within the maximal 600mg/day specified in the market authorization (400mg twice daily only in clinical trials).

Hydroxychloroquine is a weak inhibitor of CYP2D6 and of the P-gp efflux protein, requiring intensified monitoring when used concomitantly with narrow-window drugs having this metabolic pathway: gefitinib, tamoxifen (Table 2C) . A few clinically relevant pharmacokinetic drug-interactions are reported with hydroxychloroquine.

Hydroxychloroquine incurs a risk of QT prolongation and torsade de pointe occurrence when associated to other drugs with the same toxicity profile. ECG monitoring is widely established and has to be systematically done in case of certain antineoplastics (see Table 3 ) such as cabozantinib, ceritinib, crizotinib, nilotinib, osimertinib, vandetanib, vemurafenib, oxaliplatin and arsenic trioxide [85] .

Attention should also be paid to support treatments. Risk of torsade de pointe contraindicates association to ondansetron (>8mg) or domperidone (replace by metomimazine).

Antidepressants such as (es)citalopram widely prescribed for cancer patients are likewise contraindicated [86] . All torsade de pointe risks such as hypokalemia (with corticosteroids, cisplatin or other drug when associated with digestive disorders) and bradycardia (e.g., with thalidomide) should also be taken into account.

Hydroxychloroquine also incurs a risk of peripheral neuropathy. Vigilance is required for patients treated by platinum salts, anthracyclines, taxanes and immunomodulators, and even more in case of comorbidities such as diabetes mellitus or chronic alcohol abuse. Regarding the ocular toxicity of hydroxychloroquine, attention should also be required when associated with MEK inhibitors for example [87] .

Remdesivir is a nucleoside analog of adenine used against Ebola with an orphan drug status approval in the United Stated but not in Europe. It has undergone several clinical trials, in the light of in-vitro efficacy against Coronaviruses (SARS-CoV, MERS-CoV). For COVID-19, the most used dosage in clinical trials is 200mg on day 1 then 100mg daily by parenteral route for 10 days.

The interaction profile is favorable, with neither induction nor inhibition of cytochrome P450

and of the main transporters in preclinical studies so no impact is expected in this way. As a CYP3A4 substrate, the association to an inductor or inhibitor drug requires close monitoring for adverse effects (Table 2C ).

The safety profile includes nephrotoxicity and hepatotoxicity requiring dose adaptation when reduced glomerular filtration rate or transaminase elevation, respectively. Association to nephrotoxic or hepatotoxic drugs requires monitoring. Recent clinical trials reported diarrhea and hypokalemia up to 9% and 12%, respectively [88, 89] . Attention should be payed to serum potassium levels in patients taking diarrhea and/or hypokalemia-induced medicines. As anemia and thrombocytopenia can also be observed, association with antineoplastic agents with significant hematologic toxicities should be used with caution (Table 3) .

Azithromycin is a macrolide antibiotic used for COVID-19 to prevent bacterial super-infection.

Clinical practices report mainly schedules based on 500mg on day 1 followed by a daily dose of 250mg the next four days, associated, or not, to hydroxychloroquine.

Azithromycin appears to inhibit efflux protein P-gp leading to increased concentration of P-gp substrates. Caution should be taken particularly with narrow therapeutic index drugs such as cyclosporine in immunocompromised patients. Blood concentration of cyclosporine should be closely monitored.

The major risk concerns the cardiac sphere with QT prolongation and risk of torsade de pointe.

This effect is particularly feared considering the frequent association of azithromycin and hydroxychloroquine. The use of this association must be avoided with some TKIs, arsenic trioxide and antidepressant.

Interferon beta-1a is indicated in multiple sclerosis and is evaluated in DisCoVeRy trial at 44 µg at days 1, 3 and 6. It shows a very favorable interaction profile, with no cytochrome-or transporter-mediated effects. Some rare cases of autoimmune hepatitis or severe liver failure were reported. Liver monitoring should be intensified in case of association to potentially hepatotoxic drugs such as crizotinib or lenalidomide (Table 3 ). In case of at-risk associations, the Drugs.com data-base advises treatment adaptation if the alanine transaminase threshold exceeds 5 times the normal value. There is also a risk of lowering the epileptogenic threshold, as association to tramadol is strongly contraindicated, especially in at-risk patients (epilepsy, advanced age, brain tumor).

Complementary and Alternative Medicines (CAM) are widespread in cancer patients [90] , and has to be taken into account in the present crisis. Prevailing uncertainties concerning the prevention and treatment of COVID-19 stimulate use to CAM [91, 92] . The potential toxicity They include several anticancer or associated drugs such as bevacizumab, nivolumab, ruloxitinib, thalidomide, methylprednisolone and tocilizumab. Tocilizumab is an antiinterleukin-6 (IL-6) monoclonal antibody initially indicated for rheumatic disease and more recently applied in severe cytokine release syndrome induced by CAR-T cell administration

[103] for malignant hematopathy; application to COVID-19 is based on the same rationale, inhibit IL-6 pathway and consequently a part of pro-inflammatory cytokines [104] . For other drugs under assessment, a literature search was conducted ( 

Clinical 

Since the start of the crisis, hospital pharmacists have been closely involved with the medical and care teams in supplying the care and intensive care units dedicated to COVID-19. They are also involved in drawing up fast-changing treatment protocols, including alternative strategies to cope with shortages and fast-track trials assessing treatment strategies in infected patients [110] . Also, the crisis situation and mobilization of human and material resources entails a risk of inattention to cancer patients and iatrogenic risk due to distraction [21] .

Prompt implementation of clinical pharmacy in COVID-19+ units contributes to treatment optimization in the face of a theoretical risk of drug-related iatrogenesis in this novel population -risk also run by cancer patients in the COVID-19 context. The benefit of pharmaceutical expertise in cancer is well-established [111, 112, 113] , and the pandemic has led to adaptation of oncology clinical pharmacy activity: an organizational approach to limit contact-time in the care units (pharmaceutical care including consultations, medication reconciliation) and a pharmacologic approach (medication prescription analysis). Neither approach needs to be short-term with a return to business-as-usual envisaged within a matter of weeks: medium and even long-term perspectives are possible. This notably involves adapting oncology clinical pharmacy so as to set up COVID-19 pathways in hospital, including for cancer patients. This publication must be considered as a support for pharmacist to be able to act effectively for cancer patients, who tend to be polymedicated and immunodepressed. The present document provides keys for anticipating drug interactions, possible adverse effects as well as poor medication adherence in concomitant treatment of cancer patients with COVID-19. Finally, hospital and community pharmacists need to be especially alert to use of over-the-counter treatments (OTC) and CAM, as the pandemic encourages such self-medication, leading to drugrelated problems and herb-drug interactions.

Guidelines and opinions on pharmacy practice in the COVID-19 context have been published [110, 114, 115] , but none focusing on oncology pharmacy.

In Table 4 , "Ongoing clinical trials of COVID-19 treatments and implications for cancer patients".

-Maintaining pharmacy interviews and reminders of the current distancing and safety measures.

-Maintaining active involvement of pharmacists in the multidisciplinary case conferences under the same conditions as for the other participants, as advised by the French national cancer institute [116] , and in any dedicated COVID-19 multidisciplinary team meetings.

-Expertise and close collaboration with medical oncology teams in treatment strategy decision-making. This involves selection of chemotherapy protocols when the initial strategy is no longer feasible, associated recommendations (dose equivalences between parenteral and oral forms), creation of new adapted protocols (flat dose and cycle timing in immunotherapy), and providing subcutaneous forms for monoclonal antibodies (rituximab, trastuzumab). It also involves active help with support drugs, especially those leading to drug interactions (Tables 2A, 2B, 2C ).

-Deployment of telemedicine (teleconsultation and telemonitoring) to reduce face-toface pharmacy work (follow-up of patients under oral therapy) [117] .

-Exchanges with community health professionals (community pharmacists, family doctors, etc.) in a community-hospital network (switch from parenteral to oral chemotherapy, oral anticancer drugs, etc.), if possible via secure hospital-community platforms.

The present pandemic requires significant prompt adaptation. 

Reduce dose by 20 to 40 mg Induction of c elimination of ass

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Influenza vaccines in immunosuppressed adults with cancer

High mortality from viral pneumonia in patients with cancer

Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis

Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within

SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Covid-19 and long term conditions: what if you have cancer, diabetes, or chronic kidney disease?

Provisional statement: Recommendations on prevention and management of Covid-19 in patients at risk of severe forms. Rapport de l'HCSP. Paris: Haut Conseil de la Santé Publique

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Features of Postoperative Immune Suppression Are Reversible With Interferon Gamma and Independent of Interleukin-6 Pathways

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in

COVID-19 and Cancer: Do We Really Know What We Think We Know?

Case Fatality Rate of Cancer Patients With COVID-19 in a New York Hospital System

Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic

Association Between Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer: A Systematic Review of Meta-Analysis

The Relationship Between Time to Initiation of Adjuvant Chemotherapy and Survival in Breast Cancer: A Systematic Review and Meta-Analysis

three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

COVID-19 epidemic: proposed alternatives in the management of digestive cancers : A French Intergroup clinical point of view

blockade on severity of COVID-19 in patients with lung cancers

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors

Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

A Six-Weekly Dosing Schedule for Pembrolizumab in Patients With Cancer Based on Evaluation Using Modelling and Simulation

ESMO management and treatment adapted recommendations in the COVID-19 era: Lung cancer

Efficacy and Safety of First-Line Carboplatine-Versus Cisplatin-Based Chemotherapy for Non-Small Cell Lung Cancer: A meta-Analysis

Safety and Antitumour Activity of Durvalumab Plus Tremelimumab in Non-Small Cell Lung Cancer: A Multicentre, Phase 1b Study

Management of Lung Cancer During the COVID-19 Pandemic

Chemotherapy in Fisrt-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data

Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adecnocarcinoma

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomized, phase 2-3 trial

ESMO management and treatment adapted recommendations in the COVID-19 era: Gastro-oesophageal tumours

ESMO management and treatment adapted recommendations in the COVID-19 era: Breast cancer

COVID-19 and People Followed for Breast Cancer: French Guidelines for Clinical Practice of Nice

the Société Française de Sénologie et Pathologie Mammaire (SFSPM) and the French Breast Cancer Intergroup-UNICANCER (UCBG)

Francophone Myeloma Intergroup. Recommandations IFM

Multiple Myeloma in the Time of COVID-19

Patients With Newly Diagnosed Multiple Myeloma: Long-Term Follow-Up Including Ixazomib Maintenance

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients With Relapsed and Refractory Multiple Myeloma

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

Safety and Efficacu of Re-treating With Immunotherapy After Immune-Related Adverse Events in Patients With NSCLC

1297O -Randomized results of fixed-duraction (1-yr) vs continuous nivolumab in patients with advanced non-small cell lung cancer

Immune checkpoint inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions? Lung Cancer Manage

Non-steroidal anti-inflammatory drugs and covid-19

SARS: systematic review of treatment effects

Caring for patients with cancer in the COVID-19 era

Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval)

Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives

Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen

Ocular toxicities of MEK inhibitors and other targeted therapies

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Providing Oncology Pharmacy services during the coronavirus Pandemic: French Society for Oncology Pharmacy (Société Francaise de Pharmacie Oncologique-SFPO) guidelines

Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic

The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good

Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report -Ann Oncol. 2020

COVID-19 -Clinical Trials underway

A War on Two Fronts: Cancer Care in the Time of COVID-19

Concomitant drugs with low risks of drug-drug interactions for use in oncology clinical trials

COVID-19 -Clinical Trials underways -What is the recommended pathway in case of home medicines delivery

COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers

Fighting against COVID-19: Innovative strategies for clinical pharmacists

Clinical and economic impact of medication reconciliation in cancer patients: a systematic review

Pharmaceutical consultations in oncology: French Society for Oncology Pharmacy (Société Francaise de Pharmacie Oncologique -SFPO) guidelines

Apports des consultations pharmaceutiques dans la prise en charge des anticancéreux oraux

Roles of the clinical pharmacist during the COVID-19 pandemic

International Pharmaceutical Federation. FIP Covid-19 Information Hub -FIP

Guidelines for tumor board meetings in the context of Covid-19

Telemedicine in the Era of COVID-19

An exhaustive table of ongoing trials evaluating medical strategy is displayed in Appendix. The Cochrane France organization provides a website